Role of Nanoparticles in Pharmacotherapy of Cancer Therapy
DOI:
https://doi.org/10.37285/ijpsn.2016.9.1.1Abstract
Despite several dozen medications, millions of people are dying every year due to cancer. Additionally, the survival patients suffer from various serious side effects due to the use of available anticancerdrugs. The development of nanoparticle based drugs seems to be effective providing low side effects and targeted action on cancer cells. Nanoparticles are particles between 1 and 100 nanometers in size. Nanoparticles have unique biological properties given their small size and large surface area-to-volume ratio, which allows them to bind, absorb, and carry compounds such as small molecule drugs, DNA, RNA, proteins, and probes with high efficiency. Their tunable size, shape, and surface characteristics also enable them to have high stability, high carrier capacity, greater ability to incorporate both hydrophilic and hydrophobic substances, and compatibility with different administration routes, thereby making them highly attractive in many aspects of oncology.
Downloads
Metrics
Keywords:
Nanoparticles, Cancer, Carbon nanohorns, Gold nanocages, Active and Passive targeting, Theragnostics therapy.
Downloads
Published
How to Cite
Issue
Section
References
Aliabadi HM, Shahin M, Brocks DR and Lavasanifar A (2008). Disposition of drugs in block copolymer micelle delivery systems: from discovery to recovery. Clin Pharmacokinet. 47: 619-634.
Ali I, Uddin Rahis, Salim K, Rather A. M, Wani A.W and Haque A (2011). Advances in Nano Drugs for Cancer Chemotherapy. Current Cancer Drug Targets. 11: 135-146.
Alonso A, Goni FM, Buckley JT (2000). Lipids favoring inverted phase enhance the ability of aerolysm to permeabilize liposome bilayers. Biochemistry. 39(46): 14019-14024.
Bae K.H, Lee K, Kim C, and Park T.G (2011). Surface functionalized hollow manganese oxide nanoparticles for cancer targeted siRNA delivery and magnetic resonance imaging. Biomaterials. 32: 176-184.
Baker JR Jr, Choi Y (2005). Targeting cancer cells with DNA-Assembled Dendrimers a mix and match strategy for cancer. Cell Cycle. 4: 669-71.
Banerjee R (2001). Liposomes: applications in medicine. Journal of Biomaterials Applications. 16(1): 3-21.
Bardhan Rizia, Lal Surbhi, Joshi Amit and Halas J. Naomi (2011). Theranostic Nanoshells: From Probe Design to Imaging and Treatment of Cancer. Acc Chem Res. 44(10): 936-946.
Beg S, Rizwan M, Sheikh AM, Hasnain MS, Anwer K, and Kohli K (2011). Advancement in carbon nanotubes: basics, biomedical applications and toxicity. J Pharm Pharmacol. 63: 141-163.
Bernardi A, Braganhol E, Jager E, et al., (2009). Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. Cancer Lett. 281(1): 53-63.
Bhatt Jigar D, and Patel Jagruti A (2009). Cancer diagnosis and therapeutics: newer promising avenues offered by nano-technology. Pharmacologyonline. 1: 166-180.
Chen J, Saeki F, Wiley BJ, et al., (2005). Gold nanocages: bioconjugation and their potential use as optical imaging contrast agents. Nano Lett. 5: 473-477.
Cheng Y, Wang J, Rao T, He X, and Xu T (2008). Pharmaceutical applications of dendrimers: promising nanocarriers for drug delivery. Front Biosci. 13: 1447-71.
Cheng Y, Gao Y, Rao T, Li Y, and Xu T (2007). Dendrimer-based prodrugs: design, synthesis, screening and biological evaluation. Comb Chem High Throughput Screen. 10: 336-49.
Cho Kwangjae, Wang Xu, Nie Shuming, Chen (Georgia) Zhuo, and Shin M. Dong (2008). Therapeutic Nanoparticles for Drug Delivery in Cancer. Clin Cancer Res. 14(5): 1310-1316.
Christoph F. Rochlitz (2001). Gene therapy of cancer. Swiss Med Wkly. 131: 4-9.
Copland JA, Eghtedari M, Popov VL, et al. (2004). Bioconjugated gold nanoparticles as a molecular based contrast agent: implications for imaging of deep tumors using optoacoustic tomography. Mol Imaging Biol. 6: 341-349.
Couvreur P, Vauthier C (2006). Nanotechnology: intelligent design to treat complex disease. Pharm. Res. 23(7): 1417-1450.
Davis SS (1997). Biomedical applications of nanotechnology- implications for drug targeting and gene therapy. Trends Biotechnol. 15: 217-24.
Feazell RP, Nakayama-Ratchford N, Dai H, Lippard SJ (2007). Soluble single walled carbon nanotubes as longboat delivery systems for platinum (IV) anticancer drug design. J Am Chem Soc. 129: 8438-8439.
Foldvari M, and Bagonluri M (2008). Carbon nanotubes as functional excipients for nanomedicines: I. Pharmaceutical properties. Nanomedicine. 4: 173-182.
Fu HL, Cheng SX, Zhang XZ, Zhuo RX (2007). Dendrimer/DNA complexes encapsulated in a water soluble polymer and supported on fast degrading star poly(DL-lactide) for localized gene delivery. J Control Release. 124: 181-8.
Garnica-Garza H. M (2009). Contrast-enhanced radiotherapy: feasibility and characteristics of the physical absorbed dose distribution for deep-seated tumors. Physics in Medicine and Biology. 54(18): 5411-5425.
Glantz MJ, Jaeckle KA, Chamberlain MC et al. (1999). A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res. 5(11): 3394-3402.
Grayson S.M, and Frechet J.M (2001). Convergent dendrons and dendrimers: from synthesis to applications. Chem. Rev. 101(12): 3819-3868.
Gros L, Ringsdorf H, and Schupp H (1981). Polymeric Anti-Tumor Agents on a Molecular and on a Cellular-Level. Angew Chem Int. 20: 305-325.
Harris T, Maltzahn G, and Bhatia S. N (2006). Multifunctional Nanoparticles for Cancer Therapy. Nanotechnology for Cancer Therapy. 59-75.
Hirsch LR, Stafford RJ, Bankson JA, et al., (2003). Nanoshell-mediated nearinfrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA. 100: 13549-13554.
Hodge P (1993). Polymer science branches out. Nature. 362: 18-19.
Hu Jack Che-Ming, and Zhang Liangfang (2012). Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochemical Pharmacology. 83: 1104-1111.
Jaeckle KA, Batchelor T, O’Day SJ et al. (2002). An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J. Neurooncol. 57(3): 231-239.
Jain RK (1989). Delivery of novel therapeutic agents in tumors--physiological barriers and strategies. J Natl Cancer Inst. 81: 570-6.
Jain RK (2001). Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev. 46: 149-68.
Jain Vikas, Jain Shikha and Mahajan S.C (2014). Nanomedicines Based Drug Delivery Systems for Anti-Cancer Targeting and Treatment. Current drug Delivery. 11: 1-19.
Jiang Y.H. et al. (2005). SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques. AIDS Res. Hum. Retroviruses. 21: 207-213.
Jones M.C, and Leroux J.C (1999). Polymeric micelles-a new generation of colloidal drug carriers. Eur. J. Pharm. Biopharm. 48(2): 101-111.
Kagan R.A, Steckel J. R, Cancilla P, Juillard G, and Patin T (1976). The pathogenesis of brain necrosis: time and dose parameters. International Journal of Radiation OncologyBiology Physics. 1(7-8): 729-732.
KairemoKalevi, Erba Paola, Bergstrom Kim and Pauwels K.J. Ernest (2008). Nanoparticles in Cancer. Current Radio-pharmaceuticals. 1: 30-36.
Kobayashi H, Kawamoto S, Jo SK, Bryant Jr HL, Brechbiel MW, and Star RA (2003). Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. Bioconjug Chem. 14: 388-94.
Kojima C, Kono K, Maruyama K, and Takagishi T (2000). Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug Chem. 11: 910-7.
Lee J, Lee K, Moon S.H, Lee Y, Park T.G, and Cheon J (2009). All-in-one target cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery.Angew. Chem. Int. Ed. Engl. 48: 4174-4179.
Lee Y, Lee H, Kim Y.B, Kim J, Hyeon T, Park H, Messersmith P.B, and Park T.G (2008). Bioinspired surface immobilization of hyaluronic acid on monodisperse magnetite nanocrystals for targeted cancer imaging. Adv. Mater. 20: 1-4.
Li Y, Cheng Y, and Xu T (2007). Design, synthesis and potent pharmaceutical applications of glycodendrimers: a mini review. Curr Drug Discov Technol. 4: 246-54.
Liggins RT, and Burt HM (2002). Polyether-polyester diblock copolymers for the preparation of paclitaxel loaded polymeric micelle formulations. Adv Drug Deliv Rev. 54: 191-202.
Liu Z, Chen K, Davis C, et al. (2008a). Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 68: 6652-6660.
Liu Z, Davis C, Cai W, He L, Chen X, and Dai H (2008b). Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc Natl AcadSci USA. 105: 1410-1415.
Markman M (2006). Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary. Expert Opin Pharmacother. 7: 1469-74.
Matsumura Y (2008). Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. Adv Drug Deliv Rev. 60: 899-914.
Mesa A. V, Norman A, Solberg T. D, Demarco J. J, and Smathers J. B (1999). Dose distributions using kilovoltage X-rays and dose enhancement from iodine contrast agents. Physicsin Medicine and Biology. 44(8): 1955-1968.
MisraRanjita, Acharya Sarbari and Sahoo K. Sanjeeb (2010). Cancer nanotechnology: application of Nanotechnology. Drug discovery today. 15: 842-852.
Mohanraj VJ and Chen Y (2006). Nanoparticles – A Review. Tropical Journal of Pharmaceutical Research. 5(1): 561-573.
Mottram PL (2003). Past, present and future drug treatment for rheumatoid arthritis and systemic lupus erythematosus. Immunol Cell Biol. 81: 350-353.
Moussaoui N, Cansell M, and Denizot A (2002). Marinosomes, marine lipid-based liposomes: physical characterization and potential application in cosmetics. Int. J. Pharm. 242(1-2): 361-385.
Nenadis N, Zafiropoulou I, and Tsimidou M (2003). Commonly used food antioxidants: a comparative study in dispersed systems. Food Chemistry. 82(3): 403-407.
Nie S. et al., (2009). Nanotechnology applications in cancer. Annu. Rev. Biomed. Eng. 9: 257-288.
Paciotti GF, Myer L, Weinreich D, et al., (2004). Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv. 11: 169-183.
Pillai G (2014). Nanomedicines for Cancer Therapy: An Update of FDA Approved and Those under Various Stages of Development. SOJ Pharm Pharm Sci. 1(2): 13.
Praetorius P. Natalie and Mandal K. Tarun (2007). Engineered Nanoparticles in Cancer Therapy. Recent Patents on Drug Delivery & Formulation. 1: 37-51.
Rivera E (2003). Current status of liposomal anthracycline therapy in metastatic breast cancer. Clin Breast Cancer. 4: S76-83.
Rose J. H, Norman A, and Ingram M (1994). First experience with radiation therapy of small brain tumors delivered by a computerized tomography scanner. International Journal of Radiation Oncology Biology Physics. 30: 1127-1132.
Rosenthal E, Poizot-Martin I, Saint-Marc T, Spano JP, Cacoub P, and Group DNXS (2002). Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma. Am J Clin Oncol. 25: 57- 9.
Sahay G, Kim JO, Kabanov AV, et al.(2010). The exploitation of differential endocytic pathways in normal and tumor cells in the selective targeting of nanoparticulate chemotherapeutic agents [J]. Biomaterials. 31(5): 923-933.
Seow WY, Xue JM, and Yang Y.Y (2007). Targeted and intracellular delivery of paclitaxel using multifunctional polymeric micelles. Biomaterials. 28(9): 1730-1740.
Siddiqui A. Imtiaz, Adhami M. Vaqar, Christopher Jean, Chamcheu, and Mukhtar Hasan (2012). Impact of nanotechnology in cancer: emphasis on nanochemoprevention. International Journal of Nanomedicine. 7: 591-605.
Sokolov K, Follen M, Aaron J, et al. (2003). Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. Cancer Res. 63: 1999-2004.
Svenson S (2009). Dendrimers as versatile platform in drug delivery applications. Eur J Pharm Biopharm. 71: 445-62.
Svenson, S, and Tomalia, D. A (2005). Dendrimers in biomedical applications – reflections on the field. Adv. Drug Deliv. Rev. 57(15): 2106-2129.
Tan Lin Mei, Choong F.M. Peter and Dass R. Crispin (2009). Cancer, chitosan nanoparticles and catalytic nucleic acids. Journal of pharmacy and pharmacology. 61: 3-12.
Thakor S. Avnesh, and Gambhir S. Sanjiv (2013). Nanooncology: The Future of Cancer Diagnosis and Therapy. Ca Cancer J Clin. 63(6): 395-418.
Torchilin VP (2001). Structure and design of polymeric surfactant-based drug delivery systems. J Control Release. 73: 137-172.
Torchilin VP (2007). Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 9: E128-E147.
Venditto VJ, Regino CA, and Brechbiel MW (2005). PAMAM dendrimer based macromolecules as improved contrast agents. Mol Pharm. 2: 302-11.
Wang L, Zeng R, Li C, et al. (2009). Self-assembled polypeptide- block- poly (vinylpyrrolidone) as prospective drug- delivery systems [J]. Colloid Surface B. 74(1): 284-292.
Wang J, Sui M and Fan W (2010). Nanoparticles for Tumor Targeted Therapies and their Pharmacokinetics. Current Drug Metabolism. 11(2): 129-141.
Weinberg WC (2005). Development and regulation of monoclonal antibody products: Challenges and opportunities. Can Metastasis Rev. 24(4): 569-584.
Werengowska-CieTwierz Karolina, Wisniewski Marek, Terzyk P. Artur and Furmaniak Sylwester (2015). The Chemistry of Bioconjugation in Nanoparticles-Based Drug Delivery System. Advances in Condensed Matter Physics. 1-27.
Yamamoto T, Yokoyam M, Opanasopit P, Hayama A, Kawano K, and Maitani Y (2007). What are determining factors for stable drug incorporation into polymeric micelle carriers? Consideration on physical and chemical characters of the micelle inner core. J. Controlled Release. 123: 11-18.
Yotsuyanagi T, and Hazemoto N (1998). Cationic liposomes in gene delivery. Nippon Rinsho. 56: 705-12.
Young LS, Searle PF, Onion D, and Mautner V (2006). Viral gene therapy strategies: from basic science to clinical application. J. Pathol. 208: 299-318.
Zhang L, Pornpattananangku D, Hu CM, and Huang CM (2009). Development of nanoparticles for antimicrobial drug delivery. Curr. Med. Chem. 17(6): 585-594.
Zheng J et al. (2005). Nano- Cantilevers for an ultra- Sensitive Bio-Assay. NSTI- Nanotech. 1: 402-405.
